Can sulforaphane prevent the onset or slow the progression of osteoarthritis?

Davidson, Rosemary ORCID: https://orcid.org/0000-0002-6624-4011, Jupp, Orla, Bao, Yongping ORCID: https://orcid.org/0000-0002-6425-0370, MacGregor, Alexander ORCID: https://orcid.org/0000-0003-2163-2325, Donell, Simon, Cassidy, Aedin and Clark, Ian (2016) Can sulforaphane prevent the onset or slow the progression of osteoarthritis? Nutrition Bulletin, 41 (2). pp. 175-179. ISSN 1471-9827

[thumbnail of Davidson_et_al_Nutrition_Bulletin_accepted]
Preview
PDF (Davidson_et_al_Nutrition_Bulletin_accepted) - Accepted Version
Download (389kB) | Preview

Abstract

Osteoarthritis (OA) is a degenerative joint disease characterised in part by destruction of articular cartilage. There are currently no disease-modifying drugs to treat OA, with joint replacement the only treatment offered to patients at end-stage disease. With age the major risk factor for OA, the number of patients is predicted to double by 2030. An understanding of the role of bioactive molecules from the habitual diet on joint health offers a novel way in which to prevent the onset or slow the progression of OA. Our research has indicated that sulforaphane (SFN), gained from the consumption of cruciferous vegetables, particularly broccoli, could impact upon articular cartilage in laboratory models of OA because (1) it decreased the cytokine-induced expression of cartilage-degrading proteinases from chondrocytes (cartilage cells); (2) it prevented the cytokine-induced degradation of cartilage explants; and (3) it attenuated cartilage destruction in a murine model of OA. The major mechanism of action for SFN in human articular chondrocytes was inhibition of NFB, not activation of Nrf2 nor inhibition of histone deacetylases. A proof-of-principle human trial was performed to measure uptake of SFN, or its metabolites, in the human knee joint following a broccoli-rich diet, and the expression or levels of several genes and proteins in cartilage, fat and synovial fluid were also measured. Data from this trial are about to be published. Overall, these findings support the utility of SFN in the prevention or treatment of OA. The proof of this requires an appropriately designed clinical trial of pain and function which we are currently pursuing.

Item Type: Article
Uncontrolled Keywords: cartilage,dietary bioactive,osteoarthritis,sulforaphane,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies
Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Faculty of Science > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre
Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Faculty of Medicine and Health Sciences > Research Groups > Musculoskeletal Medicine
Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health
Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health
Depositing User: Pure Connector
Date Deposited: 01 Apr 2016 10:21
Last Modified: 24 Sep 2024 11:37
URI: https://ueaeprints.uea.ac.uk/id/eprint/58065
DOI: 10.1111/nbu.12207

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item